Physician profile
David I Levey
NPI 1306939517
$4,823.77
in general payments reported to CMS, 2019-2025
30 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,487 · 2020: $2,274 · 2021: $14.82 · 2022: $262 · 2023: $277 · 2024: $338 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aesculap Implant Systems, LLC | $1,970.00 | 2020 | |
| Novo Nordisk INC | $581.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $282.09 | 2019-2024 | Livalo, Seglentis |
| Amgen INC. | $236.85 | 2019-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.01 | 2019-2023 | Xifaxan, Trulance |
| Lilly USA, LLC | $175.88 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $158.62 | 2019-2020 | |
| Allergan, INC. | $139.96 | 2019-2020 | |
| Pfizer INC. | $123.10 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $114.38 | 2019-2020 | |
| Medtronic, INC. | $114.20 | 2022 | |
| Abbvie INC. | $102.92 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $100.17 | 2019-2020 | |
| Glaxosmithkline, LLC. | $75.76 | 2019-2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $69.15 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.77 | 2019-2022 | |
| Genentech USA, INC. | $37.82 | 2019 | |
| Bausch Health US, LLC | $30.14 | 2019 | |
| Insmed, INC. | $21.33 | 2025 | Arikayce |
| Esperion Therapeutics, INC. | $21.21 | 2024 | Nexletol |
| Boston Scientific Corporation | $20.82 | 2022 | |
| Gilead Sciences, INC. | $16.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.41 | 2019 | |
| Cleerly, INC. | $16.36 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Sanofi-Aventis U.S. LLC | $15.78 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.19 | 2019 | |
| Avanos Medical | $14.82 | 2021 | |
| Antares Pharma, INC. | $14.00 | 2019 | |
| Tolmar, INC. | $12.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Levey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.